Travere Therapeutics Inc. has published a new presentation outlining its recent business developments and strategic priorities. The company reported significant growth in 2025, including a 143% year-over-year increase in U.S. net product sales for FILSPARI® and total net product sales of approximately $410 million. Travere highlighted progress in rare kidney and metabolic diseases, with efforts to solidify FILSPARI’s position in the IgAN market and ongoing regulatory review for its use in FSGS. The company also announced plans to restart the pivotal HARMONY study for pegtibatinase in the first quarter of 2026 following manufacturing process optimization, and ended 2025 with approximately $323 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.